216974-75-3

216974-75-3 structure

Name: Bevacizumab
Chemical Name: Lithium 4-{[2-(diethylamino)ethyl]carbamoyl}-2-iodobenzoate
CAS Number: 216974-75-3
Molecular Formula: C₁₄H₁₈ILiN₂O₃
Molecular Weight: 396.150
Catalog: API Hormone and endocrine-regulating drugs Adrenal corticosteroids
Create Date: 2018-06-19 23:06:44
Modify Date: 2024-01-02 11:13:03
Bevacizumab, as a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used for the research of cancer[1][2].

Name	Lithium 4-{[2-(diethylamino)ethyl]carbamoyl}-2-iodobenzoate
Synonyms	Lithium 4-{[2-(diethylamino)ethyl]carbamoyl}-2-iodobenzoate Benzoic acid, 4-[[[2-(diethylamino)ethyl]amino]carbonyl]-2-iodo-, lithium salt (1:1)

Description	Bevacizumab, as a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used for the research of cancer[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	Bevacizumab-loaded hydrogel results in significant tumor reduction. Bevacizumab is taken up by other organs, including the heart, lung, and spleen. Bevacizumab accumulates higher within tumors via Bevacizumab-loaded hydrogel administration from 14 days onward as compared to the solution formulation. Bevacizumab (I.v.) solution, a typical drug clearance profile is observed where the antibody is cleared from the circulatory system with a half-life of ~4~5 days. The Bevacizumab-loaded hydrogel and the weekly administration of Bevacizumab solution inhibits tumor growth/metastasis in the peritoneal cavity, while one-time i.v. injection of Bevacizumab solution does not provide any therapeutic effect, leading to extensive tumor metastasis[2].
References	[1]. Liu W, et al. Effect of Avastin on the migration and invasion of pterygium fibroblasts. Eye Sci. 2014;29(4):214-218. [2]. Lee AL, et al. Injectable biodegradable hydrogels from vitamin D-functionalized polycarbonates for the delivery of avastin with enhanced therapeutic efficiency against metastatic colorectal cancer. Biomacromolecules. 2015;16(2):465-475.